🔎 Trials Near Me

Akèy › Limfom Difize Gwo Selil B › Minnesota

Etid klinik pou Limfom Difize Gwo Selil B nan Minnesota

16 etid pou Limfom Difize Gwo Selil B ap chèche patisipan nan sit nan Minnesota.

Vil nan Minnesota

Tèks ofisyèl etid la (Anglè)

Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma

  • Essentia Health Saint Joseph's Medical Center, Brainerd
  • Essentia Health - Deer River Clinic, Deer River
  • Essentia Health Cancer Center, Duluth
  • ak 3 plis
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Oct 1, 2026 · NCT06649812

Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia

  • Mayo Clinic Health Systems-Mankato, Mankato
  • Mayo Clinic in Rochester, Rochester
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 28, 2026 · NCT03418038

A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies

  • Mayo Clinic Rochester, Rochester
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 28, 2026 · NCT05006716

A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers

  • Mayo Clinic - Rochester, Rochester
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT07226843

A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )

  • Mayo Clinic - Rochester, Rochester
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT07101328

Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL

  • University of Minnesota Medical Center, Minneapolis
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Aug 31, 2026 · NCT06500273

Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma

  • University of Minnesota/Masonic Cancer Center, Minneapolis
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Aug 25, 2026 · NCT06536049

Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)

  • Mayo Clinic, Clinical Trials Referral Office, Rochester
Ap rekriteFaz 1/2
Laj 13 a 90 · Tout sèks · Mizajou Aug 6, 2026 · NCT06533579

A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy

  • Mayo Clinic Rochester, Rochester
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Aug 4, 2026 · NCT07188558

DALY II USA/ MB-CART2019.1 for DLBCL

  • Mayo Clinic, Rochester
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Jul 13, 2026 · NCT04792489

Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell Therapy

  • Mayo Clinic Health System in Albert Lea, Albert Lea
  • Mayo Clinic Health Systems-Mankato, Mankato
  • Mayo Clinic in Rochester, Rochester
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Jan 28, 2026 · NCT06834373

Auto Stem Cell Transplant for Lymphoma Patients

  • Masonic Cancer Center, University of Minnesota, Minneapolis
Ap rekriteFaz 2
Jiska laj 75 · Tout sèks · Mizajou Nov 4, 2025 · NCT03125642

Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment

  • Essentia Health - Deer River Clinic, Deer River
  • Essentia Health Cancer Center, Duluth
  • Essentia Health Hibbing Clinic, Hibbing
  • ak 2 plis
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Oct 20, 2025 · NCT05890352

Epcoritamab Compared to Observation for Treating B-cell Lymphoma Patients Not in Complete Remission After CD19-directed CAR-T Therapy

  • Mayo Clinic in Rochester, Rochester
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 26, 2024 · NCT06238648

Sous ClinicalTrials.gov, done yo ranmase Oct 2, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.